Design of an Emulgel for Psoriasis Focused on Patient Preferences
Source abstract
Abstract
Adherence to topical treatments is low and is known to be influenced by the vehicle properties. Betamethasone dipropionate (BD) is an anti-inflammatory steroid, used in psoriasis treatment in the form of an ointment, cream, or solution. The aim of this work was to develop a new vehicle for BD, focusing on the preferences of patients with psoriasis as a strategy to improve treatment adherence. Two vehicles with an aqueous external phase were explored: an emulgel and a hydrogel based on a cyclodextrin inclusion complex used to improve the aqueous solubility of BD. Since BD solubilization was not fully achieved in the hydrogel, only the emulgel was selected for further characterization. This new vehicle (emulgel) is characterized by its white, shiny appearance and good spreading properties. In comparison with petrolatum, a lower residue, higher evaporation rate, lower stickiness, and reduced ability to stain polyester fabric were observed. This vehicle also showed shear thinning behavior. The impact of this new vehicle on adherence to topical treatments should be further confirmed in clinical settings.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Psoriasis: Treatment and Pathogenesis · Dermatology and Skin Diseases · Nail Diseases and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Biomedical Research Centre CEBIMED/Research Centre of the Fernando Pessoa Energy, Environment and Health Research Unit FP-ENAS, Faculty of Health Sciences, University of Fernando Pessoa, 4249-004 Porto, Portugal
UCIBIO/REQUIMTE, MedTech, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
Associate Laboratory i4HB—Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
CIQUP-IMS, Department of Chemical Engineering, School of Engineering (ISEP), Polytechnic of Porto, 4200-072 Porto, Portugal
References (38)
Show source-provided references
1. Menditto, E., Orlando, V., De Rosa, G., Minghetti, P., Musazzi, U.M., Cahir, C., Kurczewska-Michalak, M., Kardas, P., Costa, E., and Sousa Lobo, J.M. (2020). Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence. Pharmaceutics, 12.10.3390/pharmaceutics12010044 ↗
2. Development and Validation of a Novel Questionnaire for Adherence with Topical Treatments in Psoriasis (QATOP)10.1007/s40257-017-0272-2 ↗
3. One in 3 prescriptions are never redeemed: Primary nonadherence in an outpatient clinic10.1016/j.jaad.2008.03.045 ↗
4. Poor adherence to medication as assessed by the Morisky Medication Adherence Scale-8 and low satisfaction with treatment in 237 psoriasis patients10.1111/1346-8138.12804 ↗
5. Patient preferences for psoriasis treatments: Impact of treatment experience10.1111/j.1468-3083.2011.04440.x ↗
6. How patients experience psoriasis: Results from a European survey10.1111/j.1468-3083.2005.01329.x ↗
7. Defining Patient Centric Pharmaceutical Drug Product Design10.1208/s12248-016-9938-6 ↗
8. Svendsen, M.T., Feldman, S.R., Tiedemann, S.N., Sorensen, A.S.S., Rivas, C.M.R., and Andersen, K.E. (2019). Psoriasis patient preferences for topical drugs: A systematic review. J. Dermatol. Treat., 1–6.
9. Patient preferences for attributes of topical anti-psoriatic medicines10.1080/09546634.2018.1544410 ↗
10. Hydrogel-mediated topical delivery of steroids can effectively alleviate psoriasis via attenuating the autoimmune responses10.1039/D1NR06001E ↗
11. Fabbrocini, G., De Simone, C., Dapavo, P., Malagoli, P., Martella, A., and Calzavara-Pinton, P. (2022). Long-term maintenance treatment of psoriasis: The role of calcipotriol/betamethasone dipropionate aerosol foam in clinical practice. J. Dermatol. Treat., 1–8. ahead of print.10.1080/09546634.2021.1998310 ↗
12. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis10.1111/jdv.17734 ↗
13. Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict10.1007/s13555-016-0119-4 ↗
14. Boeri, M., Saure, D., Schuster, C., Hill, J., Guerreiro, M., Klein, K., and Hauber, B. (2021). Impact of clinical and demographic characteristics on patient preferences for psoriasis treatment features: Results from a discrete-choice experiment in a multicountry study. J. Dermatol. Treat., 1–8.10.1080/09546634.2020.1869145 ↗
15. Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan10.1007/s41669-018-0104-1 ↗
16. Patients preferences for different corticosteroid vehicles are highly variable10.1080/09546634.2018.1473837 ↗
17. Treatment preferences and treatment satisfaction among psoriasis patients: A systematic review10.1007/s00403-018-1808-x ↗
18. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: Randomized phase IIIb PSO-INSIGHTFUL study10.1111/jdv.14515 ↗
19. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis
20. Patients’ vehicle preference for corticosteroid treatments of scalp psoriasis10.2165/00128071-200304040-00001 ↗
21. Patients with psoriasis prefer solution and foam vehicles: A quantitative assessment of vehicle preference
22. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: A Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology10.1016/j.ad.2012.12.005 ↗
23. Technological evolution of cyclodextrins in the pharmaceutical field10.1016/j.jddst.2020.102156 ↗
24. Recent expansions in an emergent novel drug delivery technology: Emulgel10.1016/j.jconrel.2013.06.030 ↗
25. Cyclodextrins in pharmaceutical formulations II: Solubilization, binding constant, and complexation efficiency10.1016/j.drudis.2015.11.016 ↗
26. Hyaluronic Acid-Mediated Drug Delivery System Targeting for Inflammatory Skin Diseases: A Mini Review10.3389/fphar.2020.01105 ↗
27. Fluhr, J.W., Berardesca, E., and Darlenski, R. (2012). Psoriasis and dry skin: The impact of moisturizers. Treatment of Dry Skin Syndrome: The Art and Science of Moisturizers, Springer.10.1007/978-3-642-27606-4_19 ↗
28. Moisturizing cream ameliorates dryness and desquamation in participants not receiving topical psoriasis treatment
29. Characterization of Polymeric Solutions as Injectable Vehicles for Hydroxyapatite Microspheres10.1208/s12249-010-9447-3 ↗
30. Recognition of the great successes of food texture research10.1111/jtxs.12442 ↗
31. Strontium-rich injectable hybrid system for bone regeneration10.1016/j.msec.2015.10.038 ↗
32. Characterization of an antioxidant surfactant-free topical formulation containing Castanea sativa leaf extract10.3109/03639045.2013.850712 ↗
33. Injectability of a bone filler system based on hydroxyapatite microspheres and a vehicle with in situ gel-forming ability10.1002/jbm.b.31066 ↗
34. Examination of the flow rheological and textural properties of polymer gels composed of poly(methylvinylether-co-maleic anhydride) and poly(vinylpyrrolidone): Rheological and mathematical interpretation of textural parameters10.1002/jps.10195 ↗
35. Textural analysis and flow rheometry of novel, bioadhesive antimicrobial oral gels10.1023/A:1012091231023 ↗
36. Mechanical properties of topical products containing bethametasone: Implications for adherence to treatment in psoriasis
37. Estimation of hedonic responses from descriptive skin sensory data by chi-square minimization10.1111/j.1745-459X.2006.00049.x ↗
38. Pooled Analysis Demonstrating Superior Patient- Reported Psoriasis Treatment Outcomes for Calcipotriene/Betamethasone Dipropionate Cream Versus Suspension/Gel